Clinical Trials
19 trialsNCT07339176 2026-05-14
OP-NEU-101
Onchilles Pharma Inc
Phase 1/2 Recruiting
NCT06237881 2026-02-18
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT03504488 2025-01-15
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Phase 1/2 Completed
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT05060432 2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2 Active not recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT06265025 2024-03-21
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
Phase 1/2 Recruiting
NCT04729543 2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2 Recruiting
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT02521870 2021-08-03
SYNERGY-001
Dynavax Technologies Corporation
Phase 1/2 Terminated